

Sartorius Stedim Biotech signs long-term syndicated loan

- **Credit volume at 250 million euros**
- **International bank syndicate led by Commerzbank and Nord/LB**

Aubagne | Goettingen, September 3, 2013 – Sartorius Stedim Biotech S.A. (SSB), a leading global supplier for the pharmaceutical and biotech industries, took out a long-term syndicated loan of 250 million euros for the next five years. The company signed the loan agreement with an international bank syndicate led by Commerzbank AG and Nord/LB. In addition, syndicate participants include BNP Paribas, Deutsche Bank, DZ Bank, HSBC, LBBW and Société Générale.

With this transaction, SSB is putting its financing on a broad-based, international footing over the long term. Peer Brauer, the Vice President of Finance, assessed the successful conclusion of this facility agreement as a mark of confidence in SSB's business model. "We are pleased that on the banking side, several international credit institutes have joined our long-term banking partners. This loan will be giving us considerable flexibility and sufficient leeway for taking further strategic measures."

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions."

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,000 people, and in 2012 earned sales revenue of 544.0 million euros.
www.sartorius.com

Contact for Sartorius Stedim Biotech

Petra Kirchhoff

Vice President of Group Communications and IR

+49.(0)551.308.3615; +49.(0)172.5603281 (mobile/cellphone)

petra.kirchhoff@sartorius.com